Hematopoiesis News Volume 7.10 | Mar 15 2016

Inductive Interactions Mediated by Interplay of Asymmetric Signaling Underlie Development of Adult Hematopoietic Stem Cells
Using a combination of ex vivo and in vivo approaches, investigators report that stage-specific reciprocal dorso–ventral inductive interactions and lateral input from the urogenital ridges are required to drive hematopoietic stem cells development in the aorta. [Nat Commun] Full Article | Press Release

Therapeutic Targeting and Rapid Mobilization of Endosteal HSC Using a Small Molecule Integrin Antagonist
Researchers showed targeting α₉β₁/α₄β₁ integrins with a single dose of a small molecule antagonist (BOP (N-(benzenesulfonyl)-L-prolyl-L-O-(1-pyrrolidinylcarbonyl)tyrosine)) rapidly mobilizes long-term multi-lineage reconstituting hematopoietic stem cell (HSC). [Nat Commun] Full Article

Frequency and Dynamics of Leukemia-Initiating Cells during Short-Term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Researchers described an ex vivo co-culture system in which the frequency of leukemic long-term culture-initiating cell can be used as a reliable read-out of leukemia-initiating cells activity over one week. [Cancer Res] Abstract

Kras Is Required for Adult Hematopoiesis
Scientists demonstrated that Kras is a major regulator of TPO and GM-CSF signaling in specific populations of hematopoietic cells and its function is required for adult hematopoiesis. [Stem Cells] Abstract

An In Vitro Model of Hemogenic Endothelium Commitment and Hematopoietic Production
Researchers designed a stromal line-free controlled culture system utilizing the embryonic pre-somitic mesoderm to obtain large numbers of endothelial cells that subsequently commit into hemogenic endothelium before undergoing endothelial-to-hematopoietic transition. [Development] Abstract

Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP4/CD26
Investigators evaluated effects of dipeptidylpeptidase4 (DPP4) inhibition (by Diprotin A) or gene deletion of hematopoietic progenitor cells (HPC) on chemokine inhibition of multi-cytokine stimulated HPCs, and on chemokine enhancing effects on single colony stimulating factors-stimulated HPC proliferation, as well as effects of DPP4-treatment of a number of chemokines. [Stem Cells Dev] Abstract

CLINICAL RESEARCH

Lenalidomide Treatment and Prognostic Markers in Relapsed or Refractory Chronic Lymphocytic Leukemia: Data from the Prospective, Multicenter Phase-II CLL-009 Trial
Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia treated on the prospective, multicenter randomized Phase-II CLL-009 trial. [Blood Cancer J] Full Article

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children (<18y) and Young Adults (18-29y) with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
Scientists retrospectively evaluated outcomes in 449 chronic myeloid leukemia patients with early disease receiving myeloablative hematopoietic cell transplantation (HCT) reported to the CIBMTR. They analyzed various factors affecting outcome specifically the effect of age and pre-HCT tyrosine kinase inhibitor in pediatric patients and young adults with the goal of identifying prognostic factors. [Biol Blood Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

From our sponsor: Isolate human immune cells in as little as 8 minutes with EasySep™ Request a sample.

FDA Grants Second Orphan Designation For VAL-083
DelMar Pharmaceuticals, Inc. announced that the FDA Office of Orphan Products Development has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma. The investigational drug candidate previously received an orphan designation for glioblastoma in the United States and in Europe. [DelMar Pharmaceuticals, Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow Positions – Leukemogenesis (The University of Alabama)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University Health Center)

Postdoctoral Fellow – Cancer Biology (National University of Singapore)

PhD Position – Leukemogenesis and Treatment Resistance (Institute for Tumor Biology and Experimental Therapy)

Translational Research Scientist – Hematology/Oncology (University of Chicago)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford Burnham Prebys Medical Discovery Institute)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.